EMA Authorised: Renvela (sevelamer carbonate) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorized Renvela (sevelamer carbonate) for the treatment of hyperphosphatemia in patients on renal dialysis, under Sanofi Winthrop Industrie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia

Drugs mentioned

• Renvela (sevelamer carbonate)

Snippet

Status: Authorised. Therapeutic area: Hyperphosphatemia;Renal Dialysis. MAH: Sanofi Winthrop Industrie. Decision date: 19/12/2024